Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1107.08 +5.00 (0.45%)
Previous Close $1102.08    52 Week High $88.16 
Open $1117.00    52 Week Low $67.88 
Day High $1122.02    P/E 256.27 
Day Low $1079.22    EPS $4.32 
Volume 3,314,672